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Abstract: The aim of the present study was to compare the effectiveness of cefuroxime, herd-specific autovaccine, and cefuroxime/herdspecific autovaccine treatments in eliminating S. aureus from the milk of 45 cows with subclinical mastitis. Prior to this study, cows with
S. aureus mastitis were divided into 3 groups of 15 cows each. Group 1 received cefuroxime, group 2 received the autovaccine, and group
3 received cefuroxime and the autovaccine. The antibiotic was infused into the teat canal, whereas the autovaccine was administrated
in the upper udder lymph node region. It was revealed that after day 35 of the treatment S. aureus was not detected in the milk of 40%
of the cows treated with antibiotic, 60% of the cows treated with the autovaccine, and 100% of the cows that underwent combined
therapy. Further observation of cows selected for the current study showed that in cows treated with both cefuroxime and a herd-specific
autovaccine S. aureus mastitis was not recorded for at least 2 years. In conclusion, this investigation revealed that the administration of
an anti-S. aureus herd-specific autovaccine into the upper udder lymph node region combined with infusion of an appropriate antibiotic
into the teat canal eliminates S. aureus and leads to prolonged udder protection against invasion by these microorganisms.
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1. Introduction
Staphylococcus aureus is considered the major etiological
factor in mammary gland inflammation (1,2). To date,
several different vaccines have been used for prophylaxis of
mastitis (3–5). Nevertheless, it was shown that commercial
anti-S. aureus vaccines administrated subcutaneously
were incapable of providing complete protection against
mastitis (6). Moreover, anatoxins based on staphylococcal
leukocidin or hemolysin triggered a large number of side
effects (7). However it should also be noted that Leitner
et al. (8) observed a statistically significant increase in the
concentration of anti-S. aureus IgG in serum and milk
as a result of Mastivac I vaccine with Freund adjuvant
administration into the upper udder lymph node region.
A range of antibiotics are used in mastitis treatment,
but due to increasing antibiotic resistance in mastitiscausing bacteria the therapy is not always effective.
Therefore, attempts have been made to use autovaccines
as an alternative to antibiotics (9). Autovaccines are
known to be useful in treating many different infections
(10), including those caused by intracellular pathogens
(11,12). S. aureus can be considered an intracellular
pathogen because it is able to survive inside neutrophils
* Correspondence: rdrozd@zut.edu.pl
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after phagocytosis (13). As phagocytosed bacteria
are inaccessible to antibiotics, antibiotic therapy can
therefore be insufficient. The administration of an
autovaccine enhances phagocytic effectiveness and leads
to the destruction of staphylococcal cells.
Preparing autovaccines for individual cows is
expensive and labor-intensive. However, as was proved
in the study by Nawrotek et al. (9), S. aureus mastitis in
a herd of cows is often caused by only one clonal type
of bacteria. Thus, in this study it was assumed that the
administration of an autovaccine containing bacteria
representing one clonal type of mastitis causing S.
aureus to all of the mastitic cows from a herd will reduce
the effort and cost of production while retaining its
effectiveness. We called this preparation a herd-specific
autovaccine.
The present study was based on the comparison of the
effectiveness of cefuroxime, a herd-specific autovaccine,
and a mixed cefuroxime/herd-specific autovaccine
treatment in the elimination of S. aureus from the milk of
cows with subclinical mastitis. The purpose of this work
was to examine which therapy leads to the most effective
elimination of S. aureus from mastitic bovine milk.

CZERNOMYSY-FUROWICZ et al. / Turk J Vet Anim Sci
2. Materials and methods
2.1. Animals
Forty-five Polish Holstein-Friesian cows from one herd in
Western Pomerania (Poland) were selected. The cows were
2–3 years old and had subclinical mastitis. The criteria to
qualify cows for the experiment were: the same stage of
lactation, inflammation limited to 2 quarters, and isolation
of S. aureus alone from milk. The diagnoses of subclinical
mastitis were provided by the local veterinarian. A
California mastitis test (Vet-Agro, Lublin, Poland) was used
as the indicator of the subclinical inflammation. Selected
animals were separated from their herd.
2.2 Isolation and identification of bacteria
The milk samples were collected from 2 infected quarters of
each cow into 1 container before treatment (day 0) and the
7, 21, and 35 days after treatment. Samples were collected
aseptically according to standards and stored at 4 °C until
proceeding. Firstly, decimal dilution with 0.85% NaCl (from
10–1 to 10–9) was performed. Then 0.1 mL of milk from
each dilution was plated onto Baird–Parker agar (Oxoid,
Cambridge, UK) and cultivated for 48 h at 37 °C. The isolates
were identified as S. aureus on the basis of the presence of
colonies on Baird–Parker agar, their biochemical properties
(api Staph, bioMérieux, Lyon, France), and their ability to
coagulate rabbit plasma and produce a clumping factor.
Additionally, all the isolates were examined by PCR using
primers for the S. aureus specific coa gene, as described by
Aarestrup et al. (14).
2.3. Analysis of the clonal relationships between strains of
S. aureus
The Random Amplified Polymorphic DNA-Polymerase
Chain Reaction (RAPD-PCR) assays were carried out as
originally described by Reinoso et al. (15) and modified later
by Nawrotek et al. (16). Briefly, the oligonucleotides OLP11
(5’-ACGATGAGCC-3’) and OLP13 (5’-ACCGCCTGCT-3’)
were used for the amplification of DNA simultaneously in
the same mixture for the purpose of acquiring a wide range
of amplicons and higher assay repeatability. Each reaction
mixture (25 µL) consisted of 1 U GoTaq DNA Polymerase
with 1X Green GoTaq Flexi Buffer (Promega, Madison, WI,
USA), 100 nM of dNTP mix (Promega), 0.4 µM of each
primer, and 50 ng of template DNA. RAPD- PCR was carried
out with the following thermal cycling conditions: an initial
denaturation of DNA at 95 °C for 5 min was followed by
40 cycles of amplification (95 °C for 1 min, 37 °C for 1.30
min, and 72 °C for 1 min), ending with a final extension
at 72 °C for 10 min. The PCR products were run on 1.5%
agarose gel electrophoresis in 1X Tris-borate-EDTA buffer,
and ethidium bromide was used as the DNA stain. Bands
were visualized under UV light and analyzed by GeneTools
software (Syngene, Cambridge, UK) using the unweighted
pair group method with arithmetic mean (UPGMA) and
Jaccard’s similarity coefficient.

2.4. Antimicrobial resistance
The susceptibility of S. aureus to antibiotics commonly
used to treat mastitis was determined with the disk
diffusion method according to the Clinical and Laboratory
Standards Institute (17). The following antibiotics were
used: amoxicillin (AMX 10 µg, Oxoid), amoxicillin with
clavulanic acid (AMC 30 µg, Oxoid), penicillin G (P 10U,
Oxoid), oxytetracycline (OT 30 µg, Oxoid), cephalexin
(CL 30 µg, Oxoid), cefuroxime (CXM 30 µg, bioMérieux),
ceftiofur (CEFTIO 30 µg, Rosco, Taastrup, Denmark),
gentamicin (CN 10 µg, Oxoid), amikacin (AK 30 µg,
Oxoid), streptomycin (S 10 µg, Oxoid), ampicillin with
cloxacillin (AX 25 µg, Oxoid), neomycin with bacitracin
and tetracycline (NBT 70 µg, Mast Diagnostics, Liverpool,
UK), penicillin with novobiocin (PEN/N 40 µg, Rosco),
and lincomycin with neomycin (LIN/N 75 µg, Rosco).
2.5. Preparation of herd-specific autovaccine
The herd-specific autovaccine was prepared from the clonal
strain of S. aureus isolated from the milk of cows selected
for the experiment. S. aureus isolate was inoculated onto
brain heart infusion agar (Oxoid) and incubated at 37 °C
for 24 h. Following incubation, bacterial colonies were
washed from the agar surface with a sterile 0.85% saline
solution. The bacterial suspension in a volume of 10 mL
was transferred to a new sterile tube, standardized to 1
McFarland standard (3 × 108 CFU/mL) and inactivated
by the addition of 0.05 mL of formalin. In order to
confirm sterility, 0.5 mL of the autovaccine was spread
onto a Columbia agar base with 5% sheep blood (Graso,
Starogard Gdański, Poland) and incubated at 37 °C for
72 h. The absence of a colony was interpreted as lack of
viable bacteria in the prepared autovaccine. The S. aureus
autovaccine was also tested for toxicity on randomly
selected white laboratory mice and revealed negative
results. The effectiveness of treatment was estimated on
the basis of the CFU of S. aureus per 1 mL of milk of the
investigated cows, according to bacteriological procedures
previously described.
Additionally, clinical observation and microbiological
examination of milk of cows from the experimental groups
were continued for 24 months.
2.6. Treatment of animals
The animals were divided into 3 groups of 15 cows each.
Each group of animals received a different kind of therapy.
Group 1 received cefuroxime (Spectrazol, Intervet,
Warsaw, Poland), group 2 received the herd-specific
autovaccine, and group 3 received both cefuroxime
(Spectrazol, Intervet) and the herd-specific autovaccine.
The antibiotic was infused into the teat canal 5 times after
milking (every 12 h). The autovaccine was administered
once (at the time of administration of the first dose of
antibiotic) in the upper udder lymph node region, in the
amount of 3 mL per node.
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2.7. Statistical analysis
Data are presented as the number of S. aureus-infected
cows before and after treatment in particular groups.
The statistical significance of the differences between the
number of S. aureus-infected cows (including the number
of CFU of S. aureus in their milk) in different groups of
treatment in the following days of the experiment was
analyzed by a chi-squared test. All statistical analyses were
conducted with Statistica 7.1 software.

number of cows that received the autovaccine and from
which S. aureus was not isolated increased to 9 (60%). The
most effective therapeutic effect was found in the group
receiving cefuroxime and the herd-specific autovaccine,
in which between days 7 and 35 all animals were free of
S. aureus. In addition, this system of therapy resulted in
long-term protection against staphylococcal mastitis, as
further observation of cows selected for the study showed
that in cows treated with the cefuroxime/herd-specific
autovaccine combination there were no signs of mastitis
observed for at least 2 years.

3. Results
All S. aureus isolates collected from milk of investigated
cows and used to produce herd-specific autovaccine
showed a typical phenotypic pattern and possessed the coa
gene. The RAPD-PCR proved also that all of these isolates
belonged to one genotype. A pattern of 6 amplification
products of RAPD-PCR, defined as a characteristic for
strains of that genotype, was published earlier by Nawrotek
et al. (16). On the basis of the antibiotic resistance analysis
it was found that all the investigated S. aureus isolates
showed high in vitro susceptibility to cefuroxime (second
generation cephalosporin). For that reason Spectrazol
(Intervet), containing 250 mg cefuroxime sodium, was
chosen for further research.
The results showing the effect of the treatment on the
elimination of S. aureus from the milk of investigated
cows in particular groups are presented in the Table.
The statistical analysis showed statistically significant
differences (P < 0.01) between the number of S. aureusinfected cows in different groups of treatment on days
7, 21, and 35 of the experiment. It was found that, in the
group receiving cefuroxime, 7 days after the last antibiotic
administration S. aureus was not found in the milk of 9
cows (60%), whereas after 21 and 35 days the number of
cows free of S. aureus decreased to 6 (40%). Furthermore,
the present study showed that, after 7 days of treatment,
S. aureus was not isolated from the milk of 6 cows
(40%) treated with herd-specific autovaccine. It is also
interesting to note that on day 35 of the experiment the

4. Discussion
In the present study we evaluated the effectiveness of
cefuroxime, herd-specific autovaccine, and cefuroxime/
herd-specific autovaccine treatment efficacy in eliminating
S. aureus mastitis in dairy cattle. We found that, in the
group receiving cefuroxime, 7 days after the last antibiotic
administration S. aureus was not isolated from milk of
9 cows (60%). Antibiotics take effect in the place where
bacterial cells are accessible and do not destroy bacteria
inside phagocytic cells. Cefuroxime inhibits peptidoglycan
biosynthesis (18), leading to the death of unphagocytized
bacteria. Nevertheless, the staphylococci located inside
phagocytic cells could survive due to lack of antibiotic
accessibility. Following the destruction of neutrophils S.
aureus multiplies, which explains why after days 21 and 35
of antibiotic treatment the number of S. aureus infectionfree cows decreased in the antibiotic group from 9 to 6
animals (40%).
The present study showed that, after 7 days of treatment,
S. aureus was not isolated from milk of 6 cows (40%)
treated with herd-specific autovaccine and after 35 days
this number increased to 9 (60%) animals. The efficacy
of the autovaccines is associated with the presence of
antigens, which are the same as the antigens on the surface
of S. aureus strains that cause the disease. Moreover, in our
study the autovaccines were administered during chronic
infection and the resulting immune reaction triggered

Table. Effect of the treatment on the elimination of S. aureus from the milk of investigated cows in particular groups.
CFU of S. aureus per 1 mL of milk
Group

before treatment
0

1–10

4

7 days after treatment

> 10

4

0

4

1–10

> 10

21 days after treatment
4

35 days after treatment

0

4

1–10

> 10

0

1–104

> 104

4

Number of cows (%)
Antibiotic

0

9 (60)

6 (40)

9 (60)

6 (40)

0 (0)

6 (40)

8 (53)

1 (7)

6 (40)

8 (53)

1 (7)

Autovaccine

0

8 (53)

7 (47)

6 (40)

8 (53)

1 (7)

8 (53)

7 (47)

0 (0)

9 (60)

6 (40)

0 (0)

Antibiotic/Autovaccine 0

5 (33)

10 (67) 15 (100) 0 (0)

0 (0)

15 (100) 0 (0)

0 (0)

15 (100) 0 (0)

χ test
2
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χ = 2.31; P = 0.31
2

χ = 13.6; P < 0.01
2

χ = 14.2; P < 0.01
2

χ = 13.6; P < 0.01
2

0 (0)
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a secondary response, which resulted in a short-time
synthesis of large amounts of highly specific antibodies
IgG2. The effectiveness of autovaccines also depends on
the place and method of their administration. The efficacy
of Mastivac I vaccine in S. aureus elimination reaches 70%
(8), whereas the effectiveness of the autovaccines used in
the current study after 35 days of administration was 60%.
The autovaccines used in our study and the Mastivac I
vaccine used by Leitner et al. (8) were administrated in the
same way: into the upper udder lymph node region. As is
well known, the upper udder lymph nodes play a strategic
role in protecting the mammary gland. It was earlier
proved that during mastitis IgG2 antibodies mainly pass
in to the mammary gland from the supramammary lymph
nodes (19). In the case of intracellular pathogens antigen
presentation is not possible and the production of IgG2 is
insufficient. Therefore, autovaccine administration enables
antigen presentation through the antigen presenting cells
to Th1 lymphocytes, which in turn stimulates B cells to
produce specific IgG2 through production of IFN-γ. The
antibodies appear more quickly after re-vaccination,
remain longer, and consist mainly of IgG2 (20–22). As
we recorded, during our experiment the supramammary
lymph nodes of cows treated with autovaccine were
enlarged for 8 days. This could be a result of a strong
reaction to immunization. Vaccination that induces an
acute Th1 response results in increased inflow of IgG2 to
the infected mammary gland and an influx of neutrophils
into the mammary gland (23). IFN-γ secreted by Th1
lymphocytes is also an important factor in an increase of
Fc receptors for IgG2 on the surface of neutrophils and
macrophages. Polymorphonuclear neutrophils play the
most important role in mammary gland protection against
microorganisms flowing into the gland and settling in the
gland tissue (24–26). The increase in phagocytic activity
observed after autovaccine administration kills the
staphylococci located in and outside neutrophils (27–29).
However, lack of full effectiveness in elimination of S.
aureus after autovaccination can be a result of defensive
strategies of S. aureus. For example, surfactant protein A

binds to the Fc fragment of immunoglobulin G making
S. aureus “invisible” to phagocytic cells. S. aureus also
produces toxins that inhibit neutrophil phagocytic activity
(30).
In the present study the most encouraging results
were found in the group receiving both cefuroxime and
the herd-specific autovaccine, in which, between days
7 and 35, all animals were free of S. aureus. In addition,
this system of therapy resulted in long-term protection
against staphylococcal mastitis, as further observation of
cows selected for the current study showed that in cows
treated with cefuroxime/herd-specific autovaccine no
signs of mastitis were observed for at least 2 years. The
influence of a combination of subcutaneous vaccination
and extended intramammary antimicrobial treatment in
elimination of chronic intramammary S. aureus infections
in lactating dairy cows were evaluated by Smith et al. (31).
These authors demonstrated a significant reduction in
mastitis cases in vaccinated and pirlimycin-treated cows,
providing evidence that an autovaccine and an antibiotic
can have synergistic action. As suggested by these
authors, the antibiotic eliminates extracellular bacteria,
whereas the vaccine stimulates synthesis of anti-S. aureus
immunoglobulin G2 and enhances phagocytic activity,
leading to digestion of engulfed (intracellular) bacteria.
To summarize, the present study revealed that the
administration of anti-S. aureus herd-specific autovaccine
into the upper udder lymph node region, combined
with infusion of the appropriate antibiotic into the teat
canal, eliminates S. aureus and leads to prolonged udder
protection against invasion by these microorganisms.
Therefore it can be concluded that a herd-specific
autovaccine administered with an antibiotic is the most
effective method in the treatment of mastitis caused by S.
aureus. Furthermore, it was also shown that a herd-specific
autovaccine could be as effective as an antibiotic, which
is of particular importance when considering rapidly
developing pathogen resistance to most of the known
antibiotics.
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